Recruiting

Phase 3

TezepelumabA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Sponsor:

AstraZeneca

Code:

NCT06883305

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Placebo

Study Details

Brief summary:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Study ID

NCT06883305

Start date

Mar 18, 2025

Status verified date

Sep, 2026

Completion date

Jun 5, 2029

Anticipated

Primary completion date

Mar 13, 2029

Anticipated

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. ≥40 to ≤80 years old
2. COPD diagnosis ≥1 year,
3. Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC <0.70 at screening
4. Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1
5. ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy
6. EOS ≥ 150 cells/μL during screening
7. CAT ≥15 at screening
8. Former or current smokers ≥10 pack-years

Exclusion Criteria:

1. Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD
2. Asthma, incl. pediatric, or ACOS
3. Any unstable disorder that can impact participants safety or study outcomes
4. Tuberculosis requiring treatment within 12 months prior V2
5. Malignancies current or past

Concomitant therapies:

Macrolides (less than 6 months)
Systemic immuno-suppressive, -modulating medications

6. LTOT >4.0 L/min or O2 saturation <89% despite LTOT

Study Design

Enrollment

990 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Dose 1 of Tezepelumab

Tezepelumab, SC, Q4W

experimental: Dose 2 of Tezepelumab

Tezepelumab, SC, Q4W

placebo comparator: Matching Placebo

Matching placebo, SC, Q4W

Interventions

Tezepelumab

Tezepelumab subcutaneous injection

Placebo

Placebo subcutaneous injection

Primary outcome measure

Annualised rate of moderate or severe COPD exacerbations [ Time Frame: Baseline up to 76 weeks ]

Central Contacts and Locations

Central contacts

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

Locations

Research Site

Recruiting

Foley, Alabama, United States, 36535

Research Site

Recruiting

Mobile, Alabama, United States, 36609

Research Site

Recruiting

Sheffield, Alabama, United States, 35660

Research Site

Recruiting

Phoenix, Arizona, United States, 85027

Research Site

Recruiting

Garden Grove, California, United States, 92844

Research Site

Recruiting

Newport Beach, California, United States, 92663

Research Site

Recruiting

Torrance, California, United States, 90502

Research Site

Recruiting

Clearwater, Florida, United States, 33765

Research Site

Recruiting

Cutler Bay, Florida, United States, 33157

Research Site

Recruiting

Cutler Bay, Florida, United States, 33189

Research Site

Recruiting

DeBary, Florida, United States, 32713

Research Site

Recruiting

Homestead, Florida, United States, 33032

Research Site

Recruiting

Miami, Florida, United States, 33125

Research Site

Recruiting

Miami, Florida, United States, 33155

Research Site

Recruiting

Miami, Florida, United States, 33175

Research Site

Recruiting

Orlando, Florida, United States, 32807

Research Site

Recruiting

Tampa, Florida, United States, 33606

Research Site

Recruiting

Tampa, Florida, United States, 33607

Research Site

Recruiting

Atlanta, Georgia, United States, 30344

Research Site

Recruiting

Lithonia, Georgia, United States, 30038

Research Site

Recruiting

Rincon, Georgia, United States, 31326

Research Site

Recruiting

Palos Hills, Illinois, United States, 60465

Research Site

Recruiting

Winfield, Illinois, United States, 60190

Research Site

Recruiting

Munster, Indiana, United States, 46321

Research Site

Recruiting

Baltimore, Maryland, United States, 21201

Research Site

Recruiting

Columbia, Maryland, United States, 21045

Research Site

Recruiting

North Dartmouth, Massachusetts, United States, 02747

Research Site

Recruiting

Farmington Hills, Michigan, United States, 48336

Research Site

Recruiting

Saint Cloud, Minnesota, United States, 56303

Research Site

Recruiting

Missoula, Montana, United States, 59808

Research Site

Recruiting

Papillion, Nebraska, United States, 68046

Research Site

Recruiting

Las Vegas, Nevada, United States, 89106

Research Site

Recruiting

Millville, New Jersey, United States, 08332

Research Site

Recruiting

Sewell, New Jersey, United States, 08080

Research Site

Recruiting

Toms River, New Jersey, United States, 08755

Research Site

Recruiting

Buffalo, New York, United States, 14215

Research Site

Recruiting

Cortland, New York, United States, 13045

Research Site

Recruiting

Horseheads, New York, United States, 14845

Research Site

Recruiting

High Point, North Carolina, United States, 27260

Research Site

Recruiting

Kings Mountain, North Carolina, United States, 28086

Research Site

Recruiting

New Bern, North Carolina, United States, 28562

Research Site

Recruiting

Winston-Salem, North Carolina, United States, 27103

Research Site

Recruiting

Columbus, Ohio, United States, 43213

Research Site

Recruiting

Oklahoma City, Oklahoma, United States, 73120

Research Site

Recruiting

DuBois, Pennsylvania, United States, 15801

Research Site

Recruiting

Philadelphia, Pennsylvania, United States, 19140

Research Site

Recruiting

Rock Hill, South Carolina, United States, 29732

Research Site

Recruiting

Franklin, Tennessee, United States, 37067

Research Site

Recruiting

Johnson City, Tennessee, United States, 37604

Research Site

Recruiting

Dallas, Texas, United States, 75254

Research Site

Recruiting

Fort Worth, Texas, United States, 76104

Research Site

Recruiting

Houston, Texas, United States, 77084

Research Site

Recruiting

Houston, Texas, United States, 77090

Research Site

Recruiting

Humble, Texas, United States, 77338

Research Site

Recruiting

Kerrville, Texas, United States, 78028

Research Site

Recruiting

Mansfield, Texas, United States, 76063

Research Site

Recruiting

Clearfield, Utah, United States, 84015

Research Site

Recruiting

Morgantown, West Virginia, United States, 26501

Research Site

Recruiting

Cudahy, Wisconsin, United States, 53110

Research Site

Recruiting

Calgary, Alberta, Canada, T3R 1W7

Research Site

Recruiting

Vancouver, British Columbia, Canada, V5Z 1M9

Research Site

Recruiting

Ajax, Ontario, Canada, L1S 2J5

Research Site

Recruiting

Burlington, Ontario, Canada, L7N 3V2

Research Site

Recruiting

Scarborough Village, Ontario, Canada, M1P 2V5

Research Site

Recruiting

Winchester, Ontario, Canada, K0C 2K0

Research Site

Recruiting

Windsor, Ontario, Canada, N8X-5A6

Research Site

Recruiting

Québec, Quebec, Canada, G1G 3Y8

Research Site

Recruiting

Québec, Quebec, Canada, G1V 4G5

Research Site

Recruiting

Saint-Charles-Borromée, Quebec, Canada, J6E 2B4

Research Site

Recruiting

Saint-Laurent, Quebec, Canada, H4R3C8

Research Site

Recruiting

Trois-Rivières, Quebec, Canada, G8T 7A1

Research Site

Recruiting

Saskatoon, Saskatchewan, Canada, S7N 0W8

More Information

Sponsor

AstraZeneca

Last update posted

Sep 3, 2026

Last verified

Sep, 2026

Keywords

COPD
Moderate COPD
Severe COPD
Very Severe COPD
chronic obstructive pulmonary disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-09-03.